Effects of canagliflozin on end-stage kidney disease and cardiovascular mortality in adults aged 50 years or older: an individual participant data meta-analysis of the CANVAS and CREDENCE trials.
Diabetes Res Clin PractAug 3, 2026 (epub)
Alessandro Felici
✦ AI-curated · Sources linked
In 30 seconds
This individual participant data meta-analysis of the CANVAS and CREDENCE trials evaluated the effects of canagliflozin on cardiovascular mortality and end-stage kidney disease in adults aged 50 years or older. The analysis included 7,990 participants and found a statistically significant 46.5% reduction in end-stage kidney disease, with a pooled hazard ratio of 0.535 (0.392-0.729).
Key findings
- Canagliflozin reduced end-stage kidney disease by 46.5%, with a pooled hazard ratio of 0.535.
- The number needed to treat at 3 years for end-stage kidney disease was 27.5 in CREDENCE.
- The pooled hazard ratio for cardiovascular mortality was 0.841, but not statistically significant.
Why it matters
Understanding the impact of canagliflozin on kidney disease and cardiovascular outcomes is crucial for managing patients with diabetes, particularly those at higher risk due to age. This evidence supports the use of SGLT2 inhibitors in this population.